Ascendis Pharma A/S (ASND) Stock Analysis
Verdict: HOLD
TransCon commercial expansion drives revenue growth, but repeated EPS misses and high debt present execution risk.
Investment score: 59/100
Analysis as of
Is Ascendis Pharma A/S stock worth reviewing? AI model thesis
The AI model rates Ascendis Pharma a HOLD (Score 59/100). Commercial expansion yields 113% revenue growth and positive FCF, but persistent quarterly EPS misses and debt balance the bullish pipeline thesis.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 58/100 (weight 15%)
Ascendis Pharma A/S opportunities and risks
What speaks for ASND
- TransCon Platform Commercial Scaling
What speaks against ASND
- Persistent Quarterly Earnings Misses
Peers and competitors
Frequently asked questions about Ascendis Pharma A/S (ASND)
Is ASND stock a good investment?
The cached TradeMates AI model rates Ascendis Pharma A/S as HOLD with an investment score of 59/100. The AI model rates Ascendis Pharma a HOLD (Score 59/100). Commercial expansion yields 113% revenue growth and positive FCF, but persistent quarterly EPS misses and debt balance the bullish pipeline thesis. This is algorithmic model output, not personal investment advice.
Is ASND stock a buy?
The TradeMates model verdict for ASND is HOLD with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.